The CCRM industry consortium represents key sectors of the Regenerative Medicine (RM) industry – pharmaceutical, devices, reagents, tools, biomaterials and cell therapies and consists of large multinationals, small-medium enterprises (SME) and emerging biotechnology companies. It provides market knowledge and a ready supply of global receptors for technologies and products generated by CCRM and its partners. The benefits of Australian companies becoming a member of the Industry consortium include:
- Increased brand recognition and awareness
- Access to potential customers at an international level
- Access to Intellectual Property (IP)
- Thought leadership
- Collaborative development and advancement of project ideas, and
- Increased engagement with the broader regenerative medicine community
- Product development team to augment academic expertise and facilities
- International industry consortium that reconciles technology push with market pull
- Network of local and international business and scientific leaders
Being part of CCRM Australia offers:
- For Industry: Access to state-of-art discoveries, facilities and expertise in Australia and through the CCRM global network. Access to clinical trial networks.
- For Academics: Business leaders and corporate partners to accelerate commercialization drawn from an international pool
- For Investors: risk-mitigated and capital-efficient product development
Resources
To learn more about CCRM Australia, download our brochure:
What Is CCRM Australia
